#otcd

Why Even After 150% Move In PhaseRx Inc. (NASDAQ:PZRX), Shares Are Still Undervalued

PhaseRx Inc. (NASDAQ:PZRX), a small $30M preclinical biotech Market Exclusive initiated coverage on back in September, just climbed 150% in a single day on news of an Orphan drug designation from the Food and Drug Administration (FDA) for its lead candidate targeting a rare genetic liver disease. In 99% of cases, this type of news wouldn’t cause such a spectacular move, especially for a…